Table 2.
Steady-state serum and alveolar TGC PK parameters in the 32 enrolled patients
| Parameter | Patients (n = 32) |
|---|---|
| Vd, L | 438.6 |
| CL, L/h | 42.1 |
| t1/2, h | 7.2 |
| Cmax, mcg/mL | 0.34 [0.15–1.03] |
| Cmin, mcg/mL | 0.09 [0.05–0.26] |
| ELF Cmax, mcg/mL* | 0.42 [0.15–1.2] |
| ELF Cmin, mcg/mL* | 0.32 [0.17–0.43] |
| ELF/plasma ratio (%), median [IQR]* | 152.9 [73.5–386.8] |
| AUC0-24, mcg h/mL | 3.61 [2.55–10.39] |
| AUC0-24/0.12 mcg/mL MIC ≥ 4.5, (%) | 100 |
| AUC0-24/0.25 mcg/mL MIC ≥ 4.5, (%) | 94 |
| AUC0-24/0.5 mcg/mL MIC ≥ 4.5, (%) | 75 |
| AUC0-24/1 mcg/mL MIC ≥ 4.5, (%) | 40.6 |
| AUC0-24/2 mcg/mL MIC ≥ 4.5, (%) | 28.1 |
| AUC0-24/0.12 mcg/mL MIC ≥ 6.96, (%) | 100 |
| AUC0-24/0.25 mcg/mL MIC ≥ 6.96, (%) | 91 |
| AUC0-24/0.5 mcg/mL MIC ≥ 6.96, (%) | 50 |
| AUC0-24/1 mcg/mL MIC ≥ 6.96, (%) | 34.4 |
| AUC0-24/2 mcg/mL MIC ≥ 6.96, (%) | 15.6 |
| AUC0-24/0.12 mcg/mL MIC ≥ 17.9, (%) | 78 |
| AUC0-24/0.25 mcg/mL MIC ≥ 17.9, (%) | 44 |
| AUC0-24/0.5 mcg/mL MIC ≥ 17.9, (%) | 25 |
| AUC0-24/1 mcg/mL MIC ≥ 17.9, (%) | 9.4 |
| AUC0-24/2 mcg/mL MIC ≥ 17.9, (%) | 3.1 |
Data are expressed as median [IQR] and N (%)
TGC tigecycline; PK pharmacokinetic; Vd volume of drug distribution, IQR interquartile range; CL drug clearance; t1/2 elimination half-life; Cmax peak plasmatic concentration; Cmin trough plasmatic concentration; ELF epithelial lining fluid; MIC minimum inhibitory concentration; AUC total drug area under the time–concentration curve
*TGC ELF concentrations were measured in 12 (1 h) and 7 (12 h) samples, respectively